TY - JOUR
T1 - Beyond the 'typical' patient
T2 - Treating attention-deficit/hyperactivity disorder in preschoolers and adults
AU - Vaughan, Brigette S.
AU - Wetzel, Martin W.
AU - Kratochvil, Christopher J.
N1 - Funding Information:
Dr Kratochvil is supported by NIMH Grant 5K23MH06612701A1. He also receives grant support from Eli Lilly, McNeil, Shire, Abbott, Pfizer and Cephalon, is a consultant for Eli Lilly, AstraZeneca, Abbott and Pfizer, and a member of the Eli Lilly speaker’s bureau. He receives study drug for an NIMH-funded study from Eli Lilly.
PY - 2008/4
Y1 - 2008/4
N2 - Attention-deficit/hyperactivity disorder (ADHD), typically affects school-aged children, but can present during the preschool years and persist into adulthood. Accurate diagnosis for preschoolers and adults requires adaptation of the current diagnostic criteria to account for differences in symptomatology across the age span. The differential diagnosis of ADHD and the pattern of psychiatric comorbidity vary with each age group and complicate diagnosis and management. To maximize outcomes clinicians must be able to accurately identify ADHD across the lifespan, and develop comprehensive, collaborative treatment plans. The Preschool ADHD Treatment Study (PATS) demonstrated the potential utility of methylphenidate for treating ADHD in preschoolers, and trials of psychostimulants and atomoxetine have shown some benefits for adults. Behavioural interventions likely have an adjunctive role in ADHD treatment for both groups. More research, however, is needed to determine the safest and most effective pharmacotherapies and psychosocial interventions for these non-typical patients.
AB - Attention-deficit/hyperactivity disorder (ADHD), typically affects school-aged children, but can present during the preschool years and persist into adulthood. Accurate diagnosis for preschoolers and adults requires adaptation of the current diagnostic criteria to account for differences in symptomatology across the age span. The differential diagnosis of ADHD and the pattern of psychiatric comorbidity vary with each age group and complicate diagnosis and management. To maximize outcomes clinicians must be able to accurately identify ADHD across the lifespan, and develop comprehensive, collaborative treatment plans. The Preschool ADHD Treatment Study (PATS) demonstrated the potential utility of methylphenidate for treating ADHD in preschoolers, and trials of psychostimulants and atomoxetine have shown some benefits for adults. Behavioural interventions likely have an adjunctive role in ADHD treatment for both groups. More research, however, is needed to determine the safest and most effective pharmacotherapies and psychosocial interventions for these non-typical patients.
UR - http://www.scopus.com/inward/record.url?scp=41749107750&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=41749107750&partnerID=8YFLogxK
U2 - 10.1080/09540260801887751
DO - 10.1080/09540260801887751
M3 - Review article
C2 - 18386204
AN - SCOPUS:41749107750
SN - 0954-0261
VL - 20
SP - 143
EP - 149
JO - International Review of Psychiatry
JF - International Review of Psychiatry
IS - 2
ER -